Population pharmacokinetic modeling estimated the typical CSF-to-plasma ratio at 0. Worth mentioning, in a phase I dose-escalating study of bictegravir that included 20 adults with chronic HIV infection, three people reported episodes of headaches . Raltegravir is the first HIV-1 integrase inhibitor to be licensed for treatment, and is currently indicated for patients with resistance to other classes of drugs . Copyright Yilmaz et al. Active drug use or dependence. Nashville, Tennessee, United States, View at Google Scholar C.
Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
The biphasic plasma pharmacokinetics of RAL, and the fact that samples were not evenly distributed during the postdosing interval corresponding to this biphasic pattern, with more samples between 0 and 4 h, may have led to some underestimation of the CSF RAL concentrations. Its pharmacokinetics allows twice daily drug administration. We explored relationships between the CSF raltegravir concentrations and other measured variables, including the plasma raltegravir concentrations, CSF albumin concentrations, the CSF: Furthermore, treatment of HIVE that is sustained in perivascular and parenchymal macrophages and microglia relies on the drug concentration in brain extracellular fluid surrounding these infected cells which may differ from CSF concentration. Some drugs that are affected by host pharmacogenetics and the resultant effect.
Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients | Request PDF
We undertook this study in order to assess the pharmacokinetics of raltegravir in the cerebrospinal fluid CSF space. This is likely due to the low BCRP protein expression in this cell system Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Researchers believe they have crossed hepatitis C off the list of factors that contribute to cognitive decline among HIV-positive people. Please enter a valid email address.